New Tests Delivering Instant, Simultaneous Results for
Syphilis, HIV, and Hepatitis C in Three Distinct Combinations to
Debut at 2014 AACC Annual Meeting
HALIFAX, July 16, 2014 /CNW/ - MedMira, Inc. (MedMira)
(TSXV: MIR) is expanding its Multiplo product line with the
addition of three new multiplex tests that deliver instant,
simultaneous, single-cartridge results for syphilis (TP), HIV, and
hepatitis C. The new tests being added to the product range
include Multiplo TP/nTP, which detects both active and historic
syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV,
which simultaneously detects syphilis, HIV and hepatitis C.
The full Multiplo line is now available in
international markets with analysis of highly regulated markets,
possibly including North America
and Europe, underway. MedMira will
showcase its full Multiplo line for the first time at the 2014
American Association for Clinical Chemistry (AACC) Annual Meeting
& Clinical Lab Expo.
The new tests all deliver instant results for
syphilis infection, a disease with an increasing global prevalence
rate. Multiplo TP/nTP and Multiplo TP/HIV/nTP take testing a step
further, providing comprehensive screening and confirmatory results
for both present and past syphilis infections. Detecting the
presence of both current and previous infections provides critical
information to help healthcare providers in determining the right
course of treatment for their patients.
"The creativity and innovation powered by our
patented RVF Technology is limitless and this expansion of our
Multiplo product range is a prime example of how the technology
enables new rapid tests to fast track through discovery, design,
and development to meet customer demands," said Dr. Kevin Jones, Senior Director Sales &
Marketing, MedMira. "The WHO has identified syphilis as a
serious global healthcare issue and our Multiplo tests will prove
invaluable in large scale testing programs targeting multiple
diseases, especially prenatal maternal initiatives. Multiplo
TP/HIV is currently under evaluation as part of the WHO
prequalification program and we look forward to working with them
to bring our newest Multiplo tests to screening programs around the
world."
The World Health Organization (WHO) estimates
that there are more than 12 million new cases of adult syphilis
each year, with an additional 500,000 cases affecting infants
through maternal transmission. It is the mission of WHO, and
many other healthcare initiatives, to decrease transmission of HIV
and syphilis from mothers to their children. With prenatal
diagnosis using Multiplo rapid tests, at risk pregnancies can be
identified within two minutes, greatly reducing the risk of
mother-to-child HIV and syphilis transmission.
MedMira at AACC
MedMira will debut its expanded Multiplo product
line at booth #2143 during the AACC taking place in Chicago from July
29-31. The Company will also showcase its Multiplo TP/HIV
and Multiplo HBc/HIV/HCV tests, which are slated for launch in the
U.S. in 2015, as well as its Reveal® single marker rapid HIV test
and Miriad™ research tools.
MedMira also invites conference attendees to
join them for the following presentations:
OEM Lecture Series - MedMira Rapid Vertical Flow
Technology: An in-depth look at how RVF Technology works and how it
can be used to produce multiplexed assays
Dr. Kevin Jones, Senior Director of
Sales & Marketing
Wednesday, July 30, 2014,
11:30 am - 11:50 am
"A Rapid and Effective Tool for Monitoring Monoclonal Antibody
Production"
Poster # A-325
Tuesday, July 29, 2014, 9:30 am - 5:00 pm
About MedMira
MedMira is a leading developer and manufacturer
of vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the Reveal®, Multiplo™ and Miriad™
brands in global markets. Based on its patented Rapid Vertical Flow
Technology™, MedMira's rapid HIV test is the first one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.